Print Page     Close Window     

SEC Filings

DEFM14A
ASTERIAS BIOTHERAPEUTICS, INC. filed this Form DEFM14A on 02/04/2019
Entire Document
 
 

 

INFORMATION ABOUT THE COMPANIES

 

BioTime, Inc.

 

BioTime, Inc.

1010 Atlantic Avenue, Suite 102

Alameda, CA 94501

Phone: (510) 521-3390

 

BioTime, Inc., a California corporation, is a clinical-stage biotechnology company targeting degenerative diseases. BioTime’s programs are based on two core proprietary technology platforms: cell replacement and cell/drug delivery. With BioTime’s cell replacement platform, BioTime is creating new cells and tissues with BioTime’s pluripotent and progenitor cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. BioTime’s cell/drug delivery programs are based upon BioTime’s proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed to provide for the transfer, retention, engraftment and metabolic support of cellular replacement therapy.

 

BioTime’s common shares are listed on NYSE American under the symbol “BTX.”

 

Additional information about BioTime and its subsidiaries is included in the documents incorporated by reference in this joint proxy statement/prospectus. See the section entitled “Where You Can Find More Information.”

 

Asterias Biotherapeutics, Inc.

 

Asterias Biotherapeutics, Inc.

6300 Dumbarton Circle

Fremont, California 94555

Phone: (510) 456-3800

 

Asterias is a clinical-stage biotechnology company dedicated to developing pluripotent stem cell-derived therapies to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. Asterias has industry-leading technology in two cell types, each with broad potential applicability: (1) oligodendrocyte progenitor cells, which become oligodendrocytes that have the potential to remyelinate axons within the central nervous system and perform other restorative functions, and (2) antigen-presenting dendritic cells, which train T-cells in the immune system to attack and destroy solid or liquid tumor cells across multiple types of cancer. Asterias currently has three clinical-stage therapeutic programs, focusing on spinal cord injury, non-small cell lung cancer and acute myeloid leukemia.

 

Asterias Common Stock is listed on the NYSE American under the symbol “AST.”

 

Additional information about Asterias is included in documents incorporated by reference in this joint proxy statement/prospectus. See the section entitled “Where You Can Find More Information.”

 

Merger Sub

 

Patrick Merger Sub, Inc.

1010 Atlantic Avenue, Suite 102

Alameda, CA 94501

Phone: (510) 521-3390

 

Patrick Merger Sub, Inc., a wholly owned subsidiary of BioTime, is a Delaware corporation that was formed on November 5, 2018 for the purpose of effecting the Merger. Upon completion of the Merger, Merger Sub will be merged with and into Asterias, with Asterias surviving as a wholly owned subsidiary of BioTime. Merger Sub has not conducted any activities other than those incidental to its formation and the matters contemplated by the Merger Agreement in connection with the Merger.

 

44

© Copyright BioTime, Inc.